ab
UBS Investment Research
US Morning Meeting Highlights
Global Equity Research
Estimate/Price Target Revisions
ANN, Inc.
, ANN.
N Roxanne Meyer, CFA p.
3
Strong Start to Q3; Multiple LT Catalysts
12-month rating: Buy (Unchanged), FY14E US$2.
21=>US$2.
29 ,...
More
ab
UBS Investment Research
US Morning Meeting Highlights
Global Equity Research
Estimate/Price Target Revisions
ANN, Inc.
, ANN.
N Roxanne Meyer, CFA p.
3
Strong Start to Q3; Multiple LT Catalysts
12-month rating: Buy (Unchanged), FY14E US$2.
21=>US$2.
29 , PT US$40.
00,
Market cap.
US$1.
66bn
Avago Technologies, AVGO.
O Steven Chin p.
4
Sales Diversity: Force to be Reckoned With
12-month rating: Buy (Unchanged), FY13E US$2.
47=>US$2.
53, FY14E
US$3.
07=>US$3.
10, PT Prior: US$42.
00 => US$44.
00, Market cap.
US$9.
07bn
EQT Corporation, EQT.
N Ronald J.
Barone p.
5
Reiterating Buy Rating
12-month rating: Buy (Unchanged), FY14E US$3.
60=>US$3.
65, PT Prior:
US$95.
00 => US$99.
00, Market cap.
US$12.
8bn
Computer Services & IT Consulting John T.
Williams p.
5
Financial Technology - Payroll: Thoughts on rates and valuation
Newcastle Investment, NCT.
N Matthew Howlett p.
6
Healthcare REIT Transformation in Full Swing - Reiterate Buy
12-month rating: Buy (Unchanged), FY13E US$0.
39=>US
Less
